Chugai Pharmabody Research
Hideaki Shimada has a background in scientific research, working as a Scientist at Pfizer Japan Inc from April 2004 to September 2007 and then as a Senior Scientist at Pfizer from October 2007 to March 2010. Hideaki transitioned to Chugai, where Hideaki worked as a Scientific Researcher from July 2010 to March 2017 before becoming the Chief Executive Officer at Chugai Pharmabody Research in April 2017.
This person is not in any offices
Chugai Pharmabody Research
1 followers
In the global medical field, there are many diseases in which there are no drug or current drugs are insufficient to address the medical needs of patients. Chugai Pharmabody Research (CPR) is a subsidiary company of Chugai Pharmaceutical in Japan, a member of Roche group, and is committed to address these unmet needs by specializing in the field of antibody drug discovery utilizing proprietary antibody engineering technologies.